IBIO Key Stats
- iBio to Present at the 26th Annual ROTH Conference on March 10, 2014 Marketwired 03/04 08:31 ET
- IBIO, INC. Files SEC form 10-Q, Quarterly Report Yahoo 02/14 07:35 ET
- 8:31 am iBio: Phase 1 Clinical Trial Begins for Malaria Vaccine Candidate Based on iBio's Proprietary Technology Yahoo 02/10 18:40 ET
- Phase 1 Clinical Trial Begins for Malaria Vaccine Candidate Based on iBio’s Proprietary Technology noodls 02/10 15:03 ET
- iBio (IBIO) Initiates Malaria Vaccine Phase 1 Street Insider 02/10 08:33 ET
- Phase 1 Clinical Trial Begins for Malaria Vaccine Candidate Based on iBio's Proprietary Technology Marketwired 02/10 08:31 ET
- iBio Adds Biotherapeutic Product for Treatment of Fibrosis to Its Proprietary Product Pipeline Marketwired 01/30 08:31 ET
- iBio Receives Allowance of Patent for HPV-Related Cancer Vaccine in China noodls 01/21 11:33 ET
- iBio, Inc. (IBIO) Gains; Co. Receives Patent Allowance for HPV-Related Cancer Vaccine in China Street Insider 01/21 08:51 ET
- iBio and Caliber Designate New Fusion Protein as Target Product Under License and Collaboration Agreement noodls 01/15 14:27 ET
IBIO Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). iBio is up 12.59% over the last year vs S&P 500 Total Return up 24.37%, ZIOPHARM Oncology down 15.40%, and Chemocentryx down 49.43%.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for IBIO
Pro Strategies Featuring IBIO
Did iBio make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: Delaware
- Incorporation Country: United States
- Incorporation State/Province: Delaware
iBio, Inc., is a biotechnology company, engaged in commercializing its proprietary platform technologies, iBioLaunch™ and iBioModulator™, and developing select product candidates derived from these platforms.